Chinese Academy of

This program represents a poliovirus vaccine candidate in Phase 3 development sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences, with internal code Tiantan-201417903. The program targets poliomyelitis, a viral infectious disease of significant public health concern, particularly in regions with incomplete immunization coverage. The modality is classified as a monoclonal antibody (mAb), though the specific mechanism of action has not been disclosed. The program completed Phase 3 testing as of May 30, 2016. The associated clinical trial NCT02785705 provides the primary evidence base for this development stage. No partner organization has been identified in available records. Regulatory approval status, projected peak sales, and consensus positioning remain undisclosed. The program's completion of Phase 3 represents a significant milestone in vaccine development, though subsequent regulatory filing status and commercial advancement have not yet been disclosed.

Poliomyelitis remains a critical global health priority despite significant progress toward eradication. Poliovirus continues to circulate in endemic regions, and the disease carries substantial morbidity and mortality risk, particularly in unvaccinated or under-vaccinated populations. Current immunization programs rely on established inactivated poliovirus vaccines (IPV) and oral poliovirus vaccines (OPV), creating ongoing demand for improved or complementary vaccine approaches. This program's development by a Chinese institution reflects the strategic importance of vaccine innovation in Asia-Pacific regions and emerging markets where polio remains a public health concern. The Phase 3 completion suggests clinical validation of immunogenicity and safety profiles. The competitive landscape includes established combination vaccines such as INFANRIX HEXA (which incorporates inactivated poliovirus component) and multiple other vaccine platforms. Market relevance extends to routine childhood immunization programs, catch-up campaigns in endemic regions, and potential use in post-exposure prophylaxis scenarios. The patient population encompasses infants, children, and potentially immunocompromised individuals requiring poliovirus protection. Commercial significance relates to the substantial global vaccine market and the strategic positioning of Chinese vaccine manufacturers in international health security frameworks.

Drug Class: Poliovirus vaccine candidate

Modality: Monoclonal antibody (mAb)

Indication: Poliomyelitis prevention

Mechanism of Action: Not yet disclosed

Target: Not yet disclosed

Route of Administration: Not yet disclosed

Related Therapies: INFANRIX HEXA (combination vaccine containing inactivated poliovirus component, approved by EMA; MAH: GlaxoSmithKline Biologicals S.A., authorization date February 12, 2026, EMEA product number EMEA/H/C/000296). Other established poliovirus vaccines include inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) formulations in routine use globally.

First Approval: Not yet disclosed

Patent Status: Not yet disclosed

China (NMPA): Program status indicates clinical trials ongoing in China, with NCT registry entries (NCT01507857, NCT02003495, NCT02302170, NCT03357289, NCT07077356) documenting multiple trial phases. Regulatory approval status has not yet been disclosed.

European Union (EMA): No EMA approval or filing status has been disclosed for the Tiantan-201417903 program. INFANRIX HEXA (containing inactivated poliovirus component) holds EMA approval (EMEA/H/C/000296, authorization date February 12, 2026, MAH: GlaxoSmithKline Biologicals S.A.).

United States (FDA): Regulatory status with the FDA has not yet been disclosed.

Japan (PMDA): Regulatory status with the PMDA has not yet been disclosed.

Overall regulatory pathway and approval timeline remain not yet disclosed.

Strategic Positioning: The Tiantan-201417903 program represents Chinese institutional capacity in vaccine development for a disease of global public health significance. Sponsorship by Xiyuan Hospital of China Academy of Chinese Medical Sciences indicates integration with traditional Chinese medical research infrastructure, potentially reflecting a distinctive development approach.

Clinical Development Status: Phase 3 completion as of May 30, 2016 represents substantial clinical validation. However, the absence of disclosed results, regulatory filings, or post-2016 milestones raises questions regarding program advancement and commercial prioritization over the past eight years.

Competitive Implications: The monoclonal antibody modality diverges from conventional poliovirus vaccine approaches (inactivated or live-attenuated). If the mAb mechanism confers advantages in immunogenicity, duration of immunity, or manufacturing, this could represent differentiation. However, without disclosed mechanism of action or comparative efficacy data, competitive positioning remains unclear relative to established IPV formulations and combination vaccines such as INFANRIX HEXA.

Regulatory Pathway Uncertainty: Absence of disclosed regulatory filings or approvals in major markets (FDA, EMA, PMDA) despite Phase 3 completion in 2016 suggests either: (1) ongoing regulatory preparation; (2) program deprioritization; or (3) focus on Chinese market approval. This ambiguity limits assessment of near-term commercial catalysts.

Future Catalysts: Potential milestones include regulatory filing announcements, Phase 3 results publication, approval in China or other emerging markets, and partnership announcements. Clinical trial registry updates (NCT07077356 remains active) may provide evidence of ongoing development activity.